|
Hi , |
|
Have you been following Filecoin? It’s a pretty awesome way to store large datasets in the cloud in a distributed way. Filecoin also happens to be our latest partner for the SynBioBeta conference. Are you a researcher that’s working with a large dataset AND actively looking to reduce cloud storage costs? Please take our 15 question survey before midnight on March Wed 29th and you can win a free pass to SynBioBeta and a VIP dinner with the Filecoin team.
Speaking of all things Decentralized - if you love DeSci as much as I do then you’ll be excited to know that Pfizer’s Michael Baran will be speaking at SynBioBeta in May. He’s the person on the Pfizer Ventures team who led the investment into VitaDAO that I wrote about in Forbes recently.
I also want to welcome our latest sponsor Molecule! Molecule is creating collaborative ecosystems, where stakeholders in drug development can work together to expedite the process of bringing novel therapeutics to patients. |
 |
|
The Oakland Marriott will be bursting at the seams this May, if you have not got your hotel room then sign up before March 31st for our block booking. If you’re still thinking of exhibiting then check out the last few remaining spots below. I can’t wait to see you there.
Are you in the business of chemicals and materials, check out who just signed up to attend SynBioBeta: Hanwha Solutions, Novozymes, Cargill, Lululemon, Mitre, P&G, Woodside Energy, RIL, Danaher, GS Holdings, Bayer AG, Allonnia, BASF, Manus Bio, Huue, DSM, LG, Maverick BioMetals and IFF. We’ll be opening our partnering app real soon so you’ll be able to setup 1:1 meetings. You can register today at www.synbiobeta.com.
Gary Shapiro is the entrepreneur who started the Consumer Electronics Show in Vegas. He’s a hero of mine and I got to attend the show for the first time this year. He talks about tradeshows being the great equalizer, where small startups can position themselves next to the large industry incumbents. That’s no different at SynBioBeta and I wanted to share our expo floor plan with you so you can see all the awesome companies who will be joining us. If you’d like to exhibit then please let Anissa Cooke know by this Friday. |
 |
|
|
|
New SynBioBeta 2023 speakers announced: |
 |
 |
-
Jake Lesnik, VP, Business Development is responsible for commercial strategy & partnering for Mekonos’ next-gen delivery platform, including for advanced cell therapies.
-
Dr. Ezhil Subbian is the Co-Founder & CEO of String Bio, a company that designs sustainable industrial products that improve global food security.
-
Andrew Fischer is the CEO of QuAIL Technologies, which develops innovative solutions to the world’s most challenging problems by harnessing the power of Artificial Intelligence and Quantum Computing.
-
Michael Baran, Executive Director, WRDM & Partner, has responsibility for growing venture investment transactions and managing equity investments aligned with future directions of Pfizer.
And now here’s the news: |
-
ARPA-H signals it’s open for business with range of new initiatives. ARPA-H announced a series of firsts that serve the agency’s mission of accelerating better health outcomes, including support of the Administration’s Cancer Moonshot initiative. Renee Wegrzyn, director of ARPA-H, will be opening the SynBioBeta 2023 conference! ARPA-H is launching a national competition on Polyplexus to identify revolutionary, evidence-based ideas to transform health and improve patient outcomes in the U.S.
-
Modern Meadow has partnered with American luxury brand Tory Burch to bring bio-based sustainable innovation to its iconic, bestselling ‘Ella’ tote. The Ella Bio collection utilizes BioFabbrica Bio-Tex, a USDA-certified bio-based material powered by Modern Meadow’s proprietary Bio-Alloy technology and has received a certification of 64% USDA biopreferred content.
- Arzeda's New Portfolio of ProSweet Enzymes™ Unlocks the Potential of Stevia by Efficiently Producing Reb D and M from Stevia Leaf Extract. Arzeda's platform combines computational design, artificial intelligence and the company's proprietary technology to create novel enzymes.
- California-based cultivated meat company GOOD Meat has received clearance from the U.S. Food and Drug Administration to bring its lab-grown chicken to market.
- Elegen Launches ENFINIA™ DNA, Rapid Long DNA Synthesis to Power the Bioeconomy New product delivers up to 7kb of high-accuracy DNA in as fast as 7 days, providing an unparalleled combination of speed, length, and quality to the synthetic biology market.
-
L’Oréal Becomes Third Global Company to Invest in Geno-led Venture for Sustainably Sourced Ingredients: Geno’s biotechnology platform will be used to develop sustainable alternatives to critical ingredients in everyday cosmetics, personal care, and cleaning products.
-
Setting aside the thorniest issues around CRISPR babies, scientists say embryo-editing research should proceed. The Francis Crick Institute was recently the site of the Third International Summit on Human Genome Editing.
-
A new control switch could make RNA therapies easier to program. Using an RNA sensor, scientists have designed a new way to trigger cells to turn on a synthetic gene. Their technique could make it possible to create targeted therapies for cancer by ensuring that synthetic genes are activated only in specific cells.
-
Designing more useful bacteria. In a step forward for genetic engineering and synthetic biology, researchers have modified E. coli bacteria to be immune to infection by all natural viruses tested so far.
-
TurtleTree Debuts Animal-Free Lactoferrin. TurtleTree, a biotechnology startup using precision fermentation to create bioactive ingredients such as animal-free milk proteins, debuted its precision-fermentation derived lactoferrin at a tasting event in San Francisco.
-
Twist Bioscience joins the United Nations (UN) Global Compact to redefine the future of sustainability, food security, and healthcare with synthetic DNA.
-
Synlogic announces positive data from the company’s Phase 2 Synpheny-1 study for phenylketonuria (PKU), and clinical data and preclinical data related to its homocystinuria (HCU) program.
I hope you have a wonderful week and that all of your DNA dreams come true. |
|
|
|
Regards,
John
---
John Cumbers
Founder, SynBioBeta |
|
|
|
|
|
Who's hiring? |
- Executive Assistant at SynBioBeta, Remote
- Director of Content at SynBioBeta, Remote
- Senior Sales Manager at SynBioBeta, Remote
- Field Applications Scientist, East Coast at DNA Script, Boston, MA
- Field Applications Scientist, San Francisco at DNA Script, San Francisco, CA
- Director, Reagents & Kits Development at DNA Script, Paris, France
- Engineering Technician, Instrument Manufacturing at DNA Script, South San Francisco, CA
- Business Developer at Ribbon Biolabs, Vienna (Austria) or Philadelphia (USA)
- Head of Production Engineering – DNA Synthesis at Ribbon Biolabs, Austria
- Disease Biology, Associate Director at Absci (Vancouver, WA)
- Experimental engineer for nanopore devices at IMEC, Belgium
- Microfluidic-electro researcher for life science technologies at IMEC, Belgium
- Microfluidics Designer Life Science Technologies at IMEC, Belgium
- Researcher Advanced Micro-Physiological Systems / Organ-on-Chip at IMEC, Belgium
- Head of People Operations at EVERY, South San Francisco, CA
- Protein Scientist at Colorifix, Norwich
|
|
|
|
|
SynBioBeta, LLC
3559 Mount Diablo Boulevard #2, Lafayette, CA 94549
info@synbiobeta.com
If you no longer wish to receive our emails, you can unsubscribe here.
Modify Your Email Preferences |
|
|
|
|
